

Identification and Elucidation of Bioactives in *Datura Stramonium* Leaves: An Insight into Drugs Discovery

Victor Eshu Okpashi^{1*}, Bridget¹, Bassey Jones¹, Eka Moses Eso¹, Kate Mlumun Ucho¹

¹Department of Biochemistry, University of Nigeria, Nigeria

*Corresponding author: Victor Eshu Okpashi, Department of Biochemistry, University of Nigeria, Nigeria; Tel: 2348037636808, E-mail: vic2reshu@gmail.com

Received date: May 17, 2021; Accepted date: September 04, 2021; Published date: September 14, 2021

Citation: Victor E O (2021) Identification and Elucidation of Bioactives in *Datura Stramonium* Leaves: An Insight into Drugs Discovery. *Transl Biomed* Vol.12 No.09.

Abstract

Medicines from plants help in treating ailments, but to utilize them effectively in the management of diseases requires the identification of potent phytochemicals relative to conventional drugs. These phytochemicals are compared with synthetic drugs in line with their treatment regimen. An investigation was designed to identify, and characterized the different phytochemicals in *Datura stramonium* (Jimson weed) leaves and compared with conventional or standard drugs. The identified phytochemicals were blasted on drugs bank website to find their correlation and relativity. Two solvent systems - Dichloromethane and 1- chlorooctadecanesurrogate were used to getting the extracts. GC/MS techniques was used to analyze the phytochemicals. The results showed 80 different phytochemicals belonging to several categories of phytochemicals - alkaloids, flavonoids, terpenoids, saponins, amine, and steroids. They also showed different percentage concentration and retention time. The flavonoid class had - 1.24% of 5H-Dibenzo[c, f][1, 2] diazepam, 3, 8 dichloro-6,11-dihydro, at 3.702 RT, Alkaloid class has - 2.98% 2,6-Dibromobenzoquinone was detected at 4.403 RT, steroid - 2.98% Acetanilide, 2-chloro-4'-nitro- at 4.403 RT was obtained and Terpene - 2.05% of Methyl .beta.-[N-methylanilino]acrylate was detected at 4.719 RT, respectively. Most of the identified phytochemicals matched with synthetic drugs and confirmed the purpose of their applicability in traditional medicine. This investigation established the reason a single extract may have a wide spectrum of effects on disease etiology. It validates the utilization of compounds in the extract for better therapeutic application, and drug delivery.

Keywords: Drugs-discovery, *Datura stramonium*, Bioactive, characterization secondary-metabolites

Introduction

There are several reports about the health benefits of herbal medicines. A lot has been tested on animal models as randomized trials in managing and controlling different ailments such as diabetes mellitus, arthritis, ulcer, cancers, and cases of flu, dysentery, and diarrhea. At most, the researcher may implicate the curative effect of the plant extract to the existence

of several bioactive including alkaloids, flavonoids, terpenes, steroids, saponins, amines, and alcohols. Considering that each of the listed phytochemicals has sub-compound or classes of compounds, one may wonder which particular type or classes of these phytochemicals could ameliorate the effects of a disease on the test organism. To bridge the gap of generalizing the implication of the plant's extract, this work investigated the phytochemicals in *Datura stramonium* (Linn) leaves. The phytochemicals were identified, quantified, and characterized. The identified phytochemicals were blasted on the conventional or synthetic drug bank website to match their correlations and relativity. Meanwhile, synthetic drugs have the descriptions of formulation, synthesis, and indication for application. The choice of this plant was due to its applications in diverse areas. Curiously, it's been as an esoteric cannabinoid in some parts of Nigeria.

The learning of natural products in the expansion of curative interaction, include aspects of stereochemistry, Biochemistry, biosynthesis, bioinformatics and biological accomplishment to providing pathologically useful compounds. Primary metabolites are plant compounds that are expressed continuously (Jamal et al., 2016 cited in Babiker et al., 2017). *Datura stramonium* is known as Jimson weed (Lee, 2007). Its family is Solanaceae, which is rich in primary metabolites. *Datura stramonium* is a weed belonging to the Apiaceae family. *Datura stramonium* plant has been described by the World Health Organization (WHO) as one whose many of its parts contain substances that can be used for the synthesis of useful drugs. The demand for the medicinal plant is aggregating because of the rising recognition of regular products (Tatini and Raja, 2017). Plants chemicals are non-nutrient bioactive mixtures in plant's parts. Phytochemicals are a defensive and blocking mediator against many deteriorating infections including ageing, and Inflammation (Debasis et al., 2015). People have been exploring plants products in pursuit of novel medicines. This has led to use of a wide quantity of curative plants to treat various ailments. The leaves of *D. stramonium* are used in asthma treatment (Pretorius and Marx, 2006; Savithamma et al., 2007). The vital naturally active constituents in *Datura stramonium* comprised of alkaloids, atropine and scopolamine. Atropine has been utilized in treating Parkinson's disease, peptic ulcers, diarrhea, and bronchial asthma (Ivancheva et al., 2006). Its vegetation mucilages and PolyVinyl Pyrrolidone mixture has been used as

matrix-forming substances for continual production of matrix remedies (Ahad et al., 2012). *D. stramonium* is a normal source of antioxidants and phytochemicals with antimicrobial activities (Akharaiyi, 2011). Its juice usually express considerable antimicrobial activity against several microorganism including *Staphylococcus aureus*, *Proteus Vulgaris*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Aspergillus niger* and *Fusarium* species (Reddy, 2009). The secondary metabolites of *D. stramonium* are vastly active against dissimilar ailments such as antidiabetic, antiviral, etc. (Nain et al., 2013). Water extract also shows insecticidal activities (Fan and Kriton, 2005). *Datura stramonium* is applied in Ayurvedic drug (Gaire and Subedi, 2013). The ethanol juice, show potent antimicrobial activities than water extracts. The leaves extracts suggest better efficacy than stem and root extract (Gachande and Khillare, 2013).

In India, about 75 % of the prescriptions are plants based (Solomon, 2015). The investigation on plant's natural products continues for the realizing a number of original energetic secondary metabolites (Ramendra and Vishnu, 2014), which has antifungal, antibacterial and anticancer activities. The basic extracts and uncontaminated compounds isolated from plant species are applied in herbal and traditional medications. Currently, it is necessary to isolate, identify and characterize novel secondary metabolites for the treatment of diverse maladies (Jalal 2016). The unidentified organic compounds in a complex mixture can be determined through the interpretation and matching their spectra with reference spectra (Rahim et al., 2018). The present work was carried out to identify some of the bioactive components in the leaves extract of *Datura stramonium* and matched with the reference spectra for the purpose of nascent drug discovery, production of drugs proper therapeutic regiment.

Materials and Methods

Collection and Identification of Plant Sample

Fresh and mature *Datura stramonium* leave, were obtained from Boki Local Government Area (LGA) of Cross River State, Nigeria. The leaves were washed with running water, and rinsed with distilled water. It was chopped into pieces, and air-dried. The dried samples were coarse using a blender. The coarse samples were stored at room temperature before extraction.

Identification and Authentication

The plant was identified by Dr. Ekpeike Solomon. He is in Biological Sciences Department, Faculty of Sciences, Cross River University of Technology, Calabar – Nigeria.

Preparation of Plant Extract

Twenty-five grams (25g) of the coarse leaves were weighed and transferred into the thimbles of the soxhlet extractor, One hundred and fifty (150 ml) normal-hexane) was measured and transferred into the round bottom flask of the soxhlet extractor. The solvent was heated to reflux through the heating mantle. After the extraction, the extracts were concentrated using a rotor for five days.

Screening of the Extract with GC/MS

A Gas Chromatography (Agilent 6890) was armed with a straight a deactivated 2 mm injector and 15 m All-tech EC-5 column (250 μ I.D., 0.25 μ film thickness). A split injection was used to inject the sample. The split ratio was set - 10:1. The oven temperature start at 35 °C, holds for 2 to 5 minutes, and ramped at 20 °C to 30 °C. The helium gas carrier was at 2 ml/minute flow rate. A GC mate II bench-top double-focusing magnetic sector was operated in electron ionization (EI) mode. TSS-20001 software was used for the analyses. Low-resolution mass spectra were attained at a determining power of 1000 (20 % height definition), while scanning starts from m/z 25 to m/z 700 at 0.3 seconds per scan with a 0.2-second inter-scan delay. High-resolution mass spectra were achieved at a resolving power of 5000 (20 % height definition) with a scanning of the magnet from m/z 65 to m/z 750 at 1 second per scan. The identification of the bioactive components of the pure compounds were matching their logged spectra with the data bank mass spectra of NIST library V 11 provided by the software of the instrument. During the analysis, the following conditions apply to the use of GC/MS techniques: GC/MS-QP2010 Agilent 6890 Plus; Ion source temperature: 200.00°C; Interface temperature: 250.00°C; Solvent cut time: 2.50 min; Detector gain mode: MS; Detector gain: 0.00 kV; Threshold: 2000; Column oven initial temperature: 70.0°C; Injection final temperature: 250.00°C; Injection Mode: Split; Flow control mode: linear velocity; Pressure: 116.9 kPa, total Flow: 40.8 ml min⁻¹; Column flow: 1.80 ml min⁻¹; Linear velocity: 49.2 cm sec⁻¹; Trap and purge flow: 3.0 ml min⁻¹; Split Ratio: 20.0; High pressure injection: OFF; Carrier Gas: Helium; Splitter hold: OFF.; While oven rating was as follows: Oven Temp. Program Rate Temperature (°C) Hold Time (min) Initial: 0.00 70.0 0.00 Final: 10.0 280 5.00.

Results

Bioactive Components Detected in *D. Stramonium* Leaves Extract

Results of bioactive analysis of *Datura Stramonium* leaves are presented in Tables designated as Table 1a, b, c, d, e, f, g, and h, separately. The Tables are indicated with peaks numbers (peak height), retention time (chromatogram peak number), area percentage (analyte concentration), library identified analytes (detected chemicals), bioactive class (secondary metabolites), reference number, CAS numbers, and minimum quality. About 80 variable bioactive were qualitatively and quantitatively detected in *D. stramonium* leaves with different concentrations. In most instances, three bioactive of the same or different metabolites will have the same peak height and area concentration, but different retention time, reference number and CAS number. For example, Table 1a have 5H-Dibenz ,f] [1,2]diazepine, 3, 8, dichloro-6, 11-dihydro whose metabolite is flavonoid had 1.24% area concentration at 3.702 retention time (minutes) on peak 1. A similar arrangement follows with other bioactive presented in Table 1b to 1h.

Peak H.	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Min. Q									
1	3.702	1.24	5H-Dibenzo[c,f][1,2]diazepine, 3,8 dichloro-6,11-dihydro- Acetyl chloride, (2,4-dichlorophenoxy)- [5-(5-Bromopyridin-3-yl)-2H-1,2,4-triazol-3-yl]acetic acid	Flavonoid - Flavonoid	124275 100763 142388	000955-66-8 000774-74-3 1000387-64-2	74 64 48							3-Bromo-4-chloro-5-methylbenzenesulfonic acid		
2	3.834	1.29	1,5-Hexadiene, 1,1,2,5,6,6-hexachloro-5-Bromo-2,3-dimethoxy-6-nitrobenzaldehyde 2,2',4',5'-Tetrachloroacetanilide	Terpenoid Flavonoid Flavonoid	146542 149053 131828	098141-62-9 1000253-65-8 023595-42-8	62 43 35		4	4.329	1.50	1H-Tetrazole, 1-ethyl-5-phenyl- Acetamide, 2-[4-(4-bromophenylthiazolyl)]-1,3,5-triazine-2-amine, 4-chloro-N-(4-ethenylphenyl)-6-methoxy-	Flavonoid Alkaloid Alkaloid	43503 154793 122371	024433-71-4 017969-16-3 1000401-58-8	53 51 51
3	4.236	0.96	2-Oxo-3-[4-bromophenyl]propanoic acid s-Triazole-3-carboxaldehyde, 5-(p-chlorophenyl)	Flavonoid - Flavonoid	104693 71809 144540	038712-59-3 026899-27-4 1000305-64-9	40 35 35		5	4.403	2.98	2,6-Dibromobenzonquinone Ethyl 5-[2-pyridyl]-4-bromopyrazolcarboxylate Acetanilide, 2-chloro-4'-nitro-	Alkaloid Pyrazole alkaloids Steroid	125049 154049 78571	019643-45-9 1000211-49-9 017329-87-2	47 38 35
									6	4.719	2.05	Methyl beta-[N-methylanilino]acrylate Methyl 2,4-tridecadiynoate Tetryl	Terpene Flavonoid Alkaloid	56745 83274 147304	084591-20-8 1000336-39-6 000479-45-8	25 18 15

7	4.818	1.38	Benz enesu lfinic acid, 4- chloro - Oxaz olidin e, 2- isopro pyl-4- [2- allyli]phen oxy]m ethyl]- Boron - difluor o(1,3- diphe nyl-1, 3- propa nediol to)-	Alkalo id - Alkalo id	4472 1 1354 72 1323 02	0001 00-03 -8 0706 87-97 -7 0149 47-61 -6	35 30 25
---	-------	------	---	-----------------------------------	---------------------------------------	---	----------------

Table 1a: Bioactive Profile of *Datura stramonium* leaves Screened with GC-MS.

Peak H	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Min. Qual.
8	4.892	7.68	4- benzo xazol e, 2- (triflu orom ethyl) - Pyridi ne, 2- (1- methy l ethyl) - Pyrrazi ne, ethen yl-	Alcohol - Amide - Alkaloid - Pyrazine	6770 9 9818 5132	1000 396-0 5-4 0006 44-98 -4 0041 77-16 -6	47 41 35
9	5.008	1.08	Ethyl 5-[4- pyridy l]-4- brom opyra zol- carbo xylate Pyrrol e-3- carbo xalde hyde, 1-(4- bro mo-3- methy l pheny l)-2,5- dimet hyl-	Alkaloid - Alkaloid - Alkaloid	1540 50 1504 89 4905 3	1000 211-5 1-2 3473 31-84 -4 0015 21-39 -7	25 25 25

			Veratr amide				
10	5.178	0.95	8- (2,3- Dimet hylani lino)n aphth o-1,2- quino ne Aceta mide, 2- chloro -N- (2,3- dihydr o -1- methy l- pyrrol o[2,3- b]quin olin-4 -yl)- Dimet hyl trans, trans- 3-(4- cyano - buta- 1,3- dienyl)isoxa zole-4 ,5- dicarb oxylat e	Alkaloid - Alkaloid - Alkaloid	1373 61 1352 85 1223 65	1000 058-0 6-7 3510 73-49 -9 1000 147-0 2-5	50 48 30
11	5.210	0.94	Terep hthalo nitrile N, N'- dioxid e 5- Brom o-6- meth oxy-2 - methy l-8- nitroq uinoli ne 4,5,6- Trichl oro-2- benzo xazol one	Alkaloid - Alkaloid - Alkaloid	3250 4 1547 89 9954 9	0037 29-34 -8 1000 214-7 0-0 0509 95-94 -3	92 38 35
12	5.320	2.66	Benz ene, 1- azido- 4- nitro- Methy l .beta -[N- methy lanilin o]acry late	Alkaloid - Alkaloid - Alkaloid	3530 2 5674 5 1473 04	0015 16-60 -5 0845 91-20 -8 0004 79-45 -8	30 25 12

Peak H.	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Min. Qual.
13	5.609	1.09	Tetryl 1,3,4-Oxadiazol-2-amine, 5-(4-bromophenyl)-Terephthalonitrile N, N'-dioxide 3(2H)-Isoquinoline, 1-amino-, oxime	Amine Flavonoid Flavonoid	101482 32504 44125	033621-62-4 003729-34-8 041536-79-2	55 53 53
14	5.641	1.41	s-Triazole-3-carboxaldehyde, 5-chlorophenyl)-2-Methyl-2,3-epoxy-2,3-dihydro-1-naphthoquinone 4-Phenyl-2-(pyrrolidine-2-yl)-1H-imidazole	Flavonoid Alkaloid Alkaloid	71809 54382 77220	026899-27-4 015448-59-6 944030-47-1	50 46 44
15	5.670	0.94	Ethane, 1-[(2-chloroethyl)thio]-2-(ethylthio)-s-Triazole-3-carboxaldehyde	Alkane Flavonoid Alkaloid	51593 71809 69825	092569-22-7 5026899-27-4 056055-54-0	90 47 45
16	5.696	0.92	hyde, chlorophenyl)-Methyl 5,6-dichloropyridine-3-carb	Flavonoid Steroid isoquinoline alkaloid Furan, nitrophenyl-, 5-oxide 5-Bromo-6-methoxy-2-methyl-8-nitroquinoline	71809 71753 154789	026899-27-4 049558-03-4 1000214-70-0	92 56 53
17	5.837	1.67	Benzesulfonic acid, 4-chloro-1H-Tetrazole, 1-ethyl-5-phenyl-5-Methyl-4-[4-(1,2,4-triazole-1-ylmethyl)phenyl]-1,2,4-triazole-3-thiol	Flavonoid Alkaloid Alkaloid	44721 43503 131973	000100-03-8 024433-71-4 1000410-40-8	53 53 49
18	6.027	1.73	9,10-Di(chloromethyl)-S-octahydroanthracene	Terpenoid Quinolone alkaloid Terpene	141786 154789 29487	018256-06-9 1000214-70-0 058679-08-6	53 38 35

Table 1b: Bioactive Profile of *Datura stramonium* leaves Screened with GC-MS.

Peak H.	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Min. Qual.
15	5.670	0.94	Ethane, 1-[(2-chloroethyl)thio]-2-(ethylthio)-s-Triazole-3-carboxaldehyde	Alkane Flavonoid Alkaloid	51593 71809 69825	092569-22-7 5026899-27-4 056055-54-0	90 47 45

			5-Bromo-6-methoxy-2-methyl-8-nitroquinoline				
19	6.052	1.09	N-(2-Phenylethyl)undeca-(2Z,4E)-diene-8,10-diyneamide	Amide Amide Terpene	137413 75605 29487	099615-80-2 040707-01-5 058679-08-6	38 35 35
20	6.558	1.12	s-Triazole-3-carboxaldehyde, chlorophenyl)-2-Methyl-2,3-epoxy-2,3-dihydro-1,4-naphthoquinone	Flavonoid Quinoline alkaloid Cyclic Alkane	71809 54382 111878	5-026899-27-4 015448-59-6 035839-71-5	68 55 53
21	6.587	1.22	5-Bromo-6-methoxy-2-	Quinoline alkaloid Alkane	154789 113828	1000214-70-0	62 59 38

			-methyl-8-nitroquinoline	Amide	137413	000115-09-3 099615-80-2	
			Mercury, chloromethyl-				
			N-(2-Phenylethyl)undeca-(2Z,4E)-diene-8,10-diyneamide				

Table 1c: Bioactive Profile of *Datura stramonium* leaves Screened with GC-MS.

Peak H.	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Minimum Quality
22	6.648	1.20	9,10-Di[chloromethyl]-S-octahydroanthracene	Alkaloid Alkaloid Alkaloid	141786 150985 185439	018256-06-9 1000260-92-6 022841-85-6	43 38 38
23	6.947	1.14	Terephthalonitrile N, N'-dioxide	Steroidal Alkaloid Steroid Steroidal Alkaloid	32504 157994 78571	003729-34-8 114724-34-4 017329-87-2	50 38 35
			Androstane-4,16-dien-3-one, 17-formyl-				
			Acetanilide,				

24	6.989	0.95	2-chloro-4'-nitro- 1,4-Dioxaspiro[4.5]deca-6,9-diene-2,8-dione 6-Bromo-4,7-dimethoxy-2H-1,3-benzodioxole-5-carbaldehyde 2-Thiophenecarbonitrile, 4-Bromo-	Terpene Aldehyde Steroidal Alkaloid	37021 147355 53820	004385-47-1 109548-10-9 1000362-65-0	50 38 35
25	7.053	1.30	Methyl 2-bromo-3-cyano-6-methylpyridine-4-carboxylate 7,8-Methylenedioxy-5-oxo-1-fluorene-9-carboxylic acid, methyl ester 2,3-Diazabicyclo[3.3.0]octa-3,7-diene-4-carboxylic acid, 2-(4-methoxyphenyl)-, ethyl ester	Alkaloid Alkaloid Alkaloid	115716 141694 145855	1000410-58-8 1000111-66-8 1000260-14-0	55 47 45
26	7.069	1.72	Acetanilide, 2-chloro-4'-nitro-7-[2-Chloroethyl]guanidine 5-Bromo-6-methoxy-2-methyl-8-nitroquinoline	Alkaloid Steroid Nucleotide Isoquinoline	78571 77363 154789	017329-87-2 022247-87-6 1000214-70-0	35 35 35
27	7.120	1.70	(3-Nitrobenzyl)-O-tolylamine 4-Amino-6-morpholinol-5-nitroimidine Phenol, 2-cyclohexyl-4,6-dinitro-	Amine Alkaloid Sapinin Sapinin	103988 88749 125969	1000296-75-0 024957-88-8 000131-89-5	56 45 44
28	7.644	1.06	(3-Nitrobenzyl)-O-tolylamine [(2-Oxochromen-4-yl)sulfonyl]acetic acid 5-Chloro-3-[(2-chloroacetyl)amino]-2-hydroxybenzo-	Amine Flavonoid Amine alkaloid	103988 97970 136837	1000296-75-0 1000410-90-7 1000294-79-5	90 40 40

			ic acid				
--	--	--	---------	--	--	--	--

Table 1d: Bioactive Profile of *Datura stramonium* leaves Screened with GC-MS.

Peak H.	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Min. Quality
29	7.773	0.98	5-Bromo-6-methoxy-2-methyl-8-nitroquinoline	Quinoline Alkaloid	154789	1000214-70-0	8345
				Alkaloid	157260	07-00577	42
				Alkaloid	135658	9-21000	
30	7.924	0.93	5-Bromo-6-methoxy-2-methyl-8-nitroquinoline	Alkaloid	154789	1000214-70-0	5545
				Alkaloid	155625	1000305-33-1	44
				Flavonoid	138442	038419-74-8	
31	8.191	0.95	4-Bromo- α -toluenesulfonic acid	Alkaloid	111885	110874-72-1	4340
				Alkaloid	148854	021133-52-8	35
				Terpene	98877	007210-71-1	
32	8.287	0.99	1,4-Dioxaspiro[4.5]deca-6,9-diene-2,8-dione	Terpene	37021	004385-47-1	9055
				Alkaloid	148348	064817-09-0	45
				Indole alkaloid	110737	1000387-20-7	

Peak H.	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Min. Quality
33	8.525	1.59	Terephthalonitrile N, N'-dioxide	Alkaloid	32504	003729-34-8	4338
				Alkaloid	145469	1000254-96-6	35
				Amide	49053	001521-39-7	
34	8.564	0.94	Benzene, pentachloronitro-Terephthalonitrile N, N'-dioxide	Alkaloid	152888	000082-68-8	4235
				Alkaloid	32504	003729-34-8	35
				Alkaloid	75605	040707-01-5	
35	8.590	1.78	5H-Dibenzo[c,f][1,2]diazepine-3,8-dichloro-6,11-dihydro-1,2,5,6-Tetrahydropyridine, 1-methyl-6-[2-pyridyl]-Benzofurazan, 4-Bromo-	Flavonoid	124275	000955-66-8	7056
				Alkaloid	42951	1000132-27-6	48
				Alkaloid	63746	035036-93-2	

Table 1e: Bioactive Profile of *Datura stramonium* leaves Screened with GC-MS.

Peak H.	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Minimum Quality
36	9.352	1.61	2-Phenyl-6-nitrochromen-3-one, oxime	Flavonoid	143624	111421-24-0	5646
				Steroid	69606	1000396-08-3	46
				-	51593	092569-22-7	
37	9.352	1.61	1(2H)-naphthalene, 3,4-dihydro-5-methoxy-2-methyl-, oxime	Flavonoid	143624	111421-24-0	5646
				Steroid	69606	1000396-08-3	46
				-	51593	092569-22-7	

46	11.039	1.43	oxy-2,3-dimethyl-1H-Benzotriazole, 4,5,6,7-tetrachloro-3-(3,4-Methylenedioxy)phenyl-4-nitrocyclohexanone 4-Methyl-6-phenyl-3-thioxo-3,4-dihydro-1,2,4-triazine-5(2H)-one	Flavonoid Flavone Alkaloid	116404 123534 82127	002338-10-5 1000111-64-4 022936-87-4	47 46 45	amine, 5-(4-bromophenyl)-1H-Tetrazole, 1-ethyl-5-phenyl-							
47	11.037	2.06	Carbazol-1-ol, 1,2,3,4-tetrahydro-6-Bromo-9-ethyl-Ethyl-4-Bromo-alpha-cyanobeta-methyl-cis-cinnamate Benzene, pentachloro nitro-	Flavonoid Terpenoid Terpenoid	152409 152287 152889	1000263-26-5 020992-89-6 000082-68-8	90 58 56	4-(4-Chlorophenyl)-3-morpholinopyrrol-2-carbaldehyde Dibenzo[b,f][1,4]diazocine, 5,6,11,12-tetrahydro-2-(trifluoromethyl)- Ethane, 1-(3,5-bromophenyl)-	Flavonoid Flavonoid Flavonoid	149595 137963 136769	142405-54-7 027188-36-9 014401-73-1	46 46 45			
48	11.069	1.06	Pyrazole, 1-methyl-3-(4-nitrophenyl)- 1,3,4-Oxadiazol-2-	Alkaloid Alkaloid Alkaloid	67254 101482 43503	073387-59-4 033621-62-4 024433-71-4	58 55 53	4,5,6-Trichloro-2-benzoxazolinone							
49	11.339	1.45													

Table 1g: Bioactive Profile of *Datura stramonium* leaves Screened with GC-MS.

Peak H.	RT	Area %	Library/ID	Metabolites	Ref no	CAS	Minimum Quality
50	11.664	1.33	Mercury, chloromethyl-5-Bromo-6-methoxy-2-methyl-8-nitroquinoline	Alkaloid Isoquinoline Isoquinoline	113828 154789 99549	000115-09-3 1000214-70-0 050995-94-3	80 62 62

51	11.850	1.03	3-Bromo-2,5-dichlorothioephene-5-Bromo-6-methoxy-2-methyl-8-nitroquinoline 3,5-Dichloro-2-hydrazinopyridine	Flavonoid Quinoline Alkaloid	93483 154789 45439	060404-18-4 1000214-70-0 104408-23-3	40 38 30	54	14.126	21.66	Phytochlorophyll-3-N-(oxolan-2-ylmethyl)-2-H-pyrrolo[3,4-c]pyridine-1,3-dimine 2,2,6-Trimethyl-1-(3-methyl-beta-1,3-dienyl)-7-oxabicyclo[4.1.0]heptan-3-ol	Alkaloid Alkaloid Flavonol	155850 151308 85557	000150-86-7 1000388-01-6 1000191-85-4	53 41 41
52	13.229	1.01	Pyrazole, 1-methyl-3-(4-nitrophenyl)- 1H-Tetrazole, 1-ethyl-5-phenyl- 1,3,4-Oxadiazol-2-amine, 5-(4-bromophenyl)-	Alkaloid Alkaloid	67254 43503 101482	073387-59-4 024433-71-4 033621-62-4	59 53 46	53	13.911	1.25	1,3,4-Oxadiazol-2-amine, 5-(4-bromophenyl)- 1H-Tetrazole, 1-ethyl-5-phenyl- s-Triazole-3-carbaldehyde, 5-chlorophenyl-	Flavonoid Alkaloid Alkaloid	101482 43503 71809	033621-62-4 024433-71-4 026899-27-4	55 53 50

Table 1h: Bioactive Profile of *Datura stramonium* leaves Screened with GC-MS.

Key: Peak height = peak H; RT = Retention time.

Discussion

An investigation to identify, quantify, and characterize the different bioactive compounds in *Datura stramonium* (Jimson weed) leaves was carried out. The results showed 80 different bioactive constituents belonging to different metabolites including alkaloids, flavonoids, terpenoids, saponins, amine and steroids. A number of phytochemicals were detected and quantified - flavonoid had - 5H-Dibenzo[c,f][1,2]diazepine - 1.24% concentration at 3.702 retention time see Table 1a. This compound is also called 3-amino-5,12,12a-trihydro-4-oxo-1H-pyrazolo[4,3-e]thiochromeno [4,3-c] [1,2] diazepines (Ramendra and Vishnu, 2014). 5H-Dibenzodiazepines are used in treating a array of health problems. They act by activating a sedative substance in the brain and central nervous system (CNS). Negative outcome may include dizziness, poor coordination, and depression (Salzman, 1990). 5H-Dibenzodiazepines are usually used for a temporary management of severe insomnia. 5H-Dibenzodiazepines remain a potent anticonvulsants and vastly effective at averting protracted epileptic seizures. The dangerous part of this leave extract is when used in combination with alcohol or opioids. (American Psychiatric Association, 1998). 5H-Dibenzodiazepines binds stereo-specifically to an exclusive portion of GABA receptors with large protein complexes, located at some neurons in the CNS. GABA is the main inhibitory neurotransmitter in the brain (Stahl, 2002). 5H-Dibenzodiazepines potentiate GABA-

mediated transmission and are indirect GABA agonists (Buffett-Jerrott and Stewart, 2002; Fick et al., 2003). A chemical class of terpenoid - 1,5-Hexadiene, 1,1,2,5,6,6-hexachloro was detected and shown in Table 1a. It has 1.29% concentration and 3.834 retention time (RT). Also, an alkaloid - 2,6-Dibromobenzoquinone commonly called Quinone, 2,6-dibromohad 2.98% at 4.403 RT. 2,6-Dibromoquinone-4-chloroimide is a reagent for the determination of phenols (Wagner et al., 2007). Katherine (2016) study the effect of halobenzoquinone on human neural stem cells (hNSCs), a flow cytometric analysis revealed that hNSCs exposed to 0.5 μ M of 2,6-dichlorobenzoquinone (2, 6- DCBQ), for 96 hours which occasioned a greater quantities of cells in S-phase. This proposes the arrest of cell cycle in the S-phase where deoxyribonucleic (DNA) replication ensues.

In Table 1b, 4-benzoxazolol, 2-(trifluoromethyl) which belongs to Chlorzoxazone family of drugs was detected in the D. stramonium leave extract. Its concentration was 7.68% at 4.892 RT. This class of chemical is an alcohol derivative which acts as muscle relaxant bearing tranquilizing properties. It is claimed to prevent muscle twinge by causing an effect mostly at the spinal cord and subcortical areas (Martindale, <https://www.drugbank.ca/drugs/DB00356>). A series of ten different oxadiazole analogues were appraised for their *in vitro* activities against cancer in single-dose assay. The oxadiazole equivalents exhibited reasonable activity against cancer on several cell lines. The oxadiazole analogues increase their anticancer activities (Mohamed et al., 2013). Another alkaloid - 4-Phenyl-2-(pyrrolidin-2-yl)-1H-imidazole whose IUPAC name is 5-phenyl-1H-imidazole was detected and estimated as 1.41% at 5.641 RT. 5-phenyl-1H-imidazole 4.41% at 5.641 RT; 1,3,4-Oxadiazol-2-amine 1.09% at 5.609 RT and s-Triazole-3-carboxaldehyde, 5-chlorophenyl were detected. There are supplemented as azole antifungal agents. They work by obstructing the making of ergosterol, a vital constituent of cell membranes in fungal. Its actions is by disrupting the cytochrome p450 51 (Lanosterol 14-alpha demethylase) in fungal. This is crucial in the structure of the cell membranes of fungus. Its inhibition resulted into cell lysis (Tassaneeyakul et al., 1998). The inhibition in the production of ergosterol, causes holes to appear in cell membrane. This is because cell membranes are necessary for the survival of fungi. There general functions include Steroid hydroxylase action, which break down more than a few precarcinogens, tablets, and diluents to reactive metabolites (Tassaneeyakul et al., 1998; Monostory et al., 2004).

Furazan, nitrophenyl-, 5-oxide 0.92% at 5.696 RT. This compound is an organic compounds - nitrobenzenes. They contain a nitrobenzene moiety, this bioactive play a vital role on metalloaminopeptidase activity by removing the N-terminal of methionine from an emerging protein. The N-terminal of methionine is repeatedly sliced when the second residue in the primary sequence is lesser and uncharged (Met-Ala-, Cys, Gly, Pro) Berman et al. (2000). 5 -Bromo-6-methoxy-2-methyl-8-nitroquinoline (Quinoline *alkaloid*) 1.22% at 6.587 RT. This is an organic compound known as nitroquinolines. It contains a nitro group bonded to a quinoline (Pelletier et al., 1994) see Table 1c. This phytochemical had exhibits antitumor activity via inhibiting the type-2 methionine of aminopeptidase (MetAP2) protein

involved in angiogenesis. Its antibacterial action originates from the metal ion complexation that is useful for bacterial growth (Pelletier et al., 1995; Shim et al., 2010).

In Table 1d, most important bioactive were detected and estimated. For example, androstan-4, 16-dien-3-one,17-formyl 1.14% at 6.947 RT is categorize as androstanes. This compound belongs to androgens and derivative, they are 3-hydroxylated C19 steroid hormones. Known to service the development of masculine characteristics, this accounted for its utilization as an esoteric cannabinoid by some youths (Chen et al., 2000). These same properties corroborate the use of this plant extract for the treatment of hair loss in humans, and function in Steroid hormone receptors - ligand-activated transcription factors that control the expression of eukaryotic gene and affect cellular proliferation and differentiation in target tissues (Takahashi et al., 2004). 2, 5-Cyclohexadiene-1,4-dione with 0.95% at 8.191 RT is also called RH-1. These are organic compounds known as p-benzoquinones. Benzoquinones have two C=O groups attached to carbon 1- and 4-positions, respectively. RH-1 has been used in trials studying the handling of Progressive Hard Cancers and Non-Hodgkin's Lymphoma (Tudor et al., 2005). At the superoxide dismutase activity, the enzyme help as a quinone reductase by linking with conjugation reactions of hydroquinons that is involved in detoxification corridors and biosynthetic routes including the vitamin (Overington et al., 2006; Imming et al., 2006). l]piperidine o-Veratramide 1.59% at 8.525 RT. This compound belongs to aminopiperidines. They contain piperidine that carries an amino group. At the triglyceride lipase activity pathway, l]piperidine is applied in the decontamination of xenobiotics and activation prodrugs containing ester and amide.

In Table 1e, tricyclic dibenzodiazepine, categorized as an uncommon antipsychotic agent (5H-Dibenzo[c,f][1,2]diazepine, 3-dichloro-6,11-dihydro-) was detected and quantified – 1.78% at 8.590 RT. This compound binds to some receptors at the central nervous system and displays a distinctive pharmacological effect. 5H - Dibenzo[c,f][1,2]diazepine is a serotonin antagonist, with high binding to 5-HT 2A/2C receptor subtype (Berman et al., 2000; Weizman et al., 2003;). It also displays high affinity to numerous dopaminergic receptors, but expresses weak antagonism at the dopamine D2 receptor, a receptor that controls neuroleptic activity (Guarrera, 1999). The major adverse effect associated with the administration of this agent is agranulocytosis (an acute febrile condition noticeable by severe reduction in blood granulocytes and often linked with the use of certain drugs). Dibenzo[c,f][1,2]diazepine is a psychotropic agent belonging to benzisoxazole derivatives indicated for the treatment of schizophrenia (a mental disorder that is characterized by disturbances in thought in the case of hallucination). 5H - Dibenzo[c,f][1,2]diazepine is a discriminating monoaminergic antagonist with strong affinity for the serotonin Type-2 (5HT2), dopamine Type-2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors (Young et al., 2004). 5H-Dibenzo[c,f][1,2]diazepine serves as an antagonist to other receptors sites, but with lesser potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities explain the side effect of 5H-Dibenzo[c,f][1,2]diazepine's (Stonehouse and Jones, 2005). 5H-Dibenzo[c,f][1,2]diazepine's antagonism of muscarinic M1-5 receptors explain its anticholinergic outcome

after administration or ingestion. 5H-Dibenzo[c,f][1,2]diazepine's antagonism of histamine H1 receptors elucidate the somnolence experience with this drug. 5H-Dibenzo[c,f][1,2]diazepine's antagonism of adrenergic-1 receptors could clarify the orthostatic hypotension observed with this bioactive (Takano et al., 2006). 5H-Dibenzo[c,f][1,2]diazepine's antipsychotic action is prospectively regulated via a combination of antagonistic effects at D2 receptors in the mesolimbic pathway and 5-HT2A receptors in the frontal cortex (Chen et al., 2002). The D-2 antagonism could relieve a helpful symptom while 5-HT2A antagonism alleviates harmful symptoms.

A 1.61% at 9.352 RT of 1(2H)-naphthalenone, 3,4-dihydro-5 was detected. It is called 2-[4-(4-Chlorophenyl)Cyclohexylidene]-3,4-Dihydroxy-1(2h)-Naphthalenone. Its mechanism of action deals ubiquinone binding to catalyzes the transformation of dihydroorotate to orotate, while quinone will remain electron acceptor (Berman et al., 2000). Phenyl-2H-chromene derivatives are derivative to synthesize triazole and biotin-containing chromene derivatives, to facilitate purification of protein targets (Bhaskar et al., 2010). These organic compounds are phenol ethers. They are aromatic compounds having ether group substituted with a benzene ring. Its derivatives is 6-(2-phenoxyethoxy)-1, 3, 5-triazine-2, 4-diamine. It function deals with acetylation of coenzyme-A carboxylase complex. Where at first, biotin carboxylase will catalyze the carboxylation of the carrier protein and then the transcarboxylase transfers the Ca⁺ (Berman et al., 2000), find Table 1f.

A flavonoid named 4-(1-Benzofuran-2-yl)-7-methoxychromen-2-one had 1.21% at 9.988 RT was detected in *D. stramonium* leaves. This compound is a flavone whose backbone is 2-phenylchromen-4-one (2-phenyl-1-benzopyran-4-one) (Shimada et al., 2009). It has antibiotic activity (for Gram-positive bacteria) and antitumor activity (for some mouse tumors). It binds non-covalently to a chromophore which is the cytotoxic and mutagenic component of the antibiotic. The chromophore in turn binds to DNA as a weak intercalator and reasons a single - and double - strand breakdown (Shimada et al., 2010).

2-Chloro-5-methyl-4, 6-bis (2-thienyl) pyrimidine 1.25% at 10.001 RT was obtained from *D. stramonium* leaves and presented in Table 1g. This organic compound is known as aminobenzenesulfonamides (Derewlany et al., 1994). They contain benzenesulfonamide moiety with an amine group bonded to the benzene ring. This amide is directed for the treatment of bacterial infections which causes bronchitis, prostatitis and urinary tract infections. The role of 2-Chloro-5-methyl-4,6-bis(2-thienyl) pyrimidine is to inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydroptericoic acid by opposing PABA from binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is usually needed to synthesize purines and dTMP. Any disruption of its synthesis will inhibit the growth of bacterial. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, additional pace in THF synthesis, and act in synergy with 2-Chloro-5-methyl-4,6-bis(2-thienyl) pyrimidine. 2-Chloro-5-methyl-4,6-bis(2-thienyl) pyrimidine has a side effect

which may be nausea, vomiting, diarrhea and hypersensitivity reactions (Friaiza et al., 2010). Hematologic effects such as anemia, agranulocytosis, thrombocytopenia and hemolytic anemia in patients with glucose-6-phosphate dehydrogenase insufficiency may arise (Bratlid and Bergan, 1976). 2-Chloro-5-methyl-4,6-bis(2-thienyl) pyrimidine might dislodge bilirubin from albumin binding sites triggering jaundice or kernicterus in newborns (Angelakou et al., 1993).

In Table 1h, 5-Bromo-6-methoxy-2-methyl-8-nitroquinoline 1.33% at 11.664 RT was obtained. This compound is nitroquinolines and its derivatives. They contain a nitro group bonded to a quinoline. It is indicated for dealing with Schistosomiasis affected by *Schistosoma mansoni* (Filho et al., 2006). 5-Bromo-6-methoxy-2-methyl-8-nitroquinoline is an anthelmintic with schistosomicidal activity against *Schistosoma mansoni*, but not against other *Schistosoma* spp. 5-Bromo-6-methoxy-2-methyl-8-nitroquinoline causes worms to move from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release egg (Overington et al., 2006). 5-Bromo-6-methoxy-2-methyl-8-nitroquinoline may link with an irreversible inhibitor of the nucleic acid metabolism. A premise has been put forth that the drug is activated by a single step, in which a schistosome sulfotransferase enzyme converts 5-Bromo-6-methoxy-2-methyl-8-nitroquinoline into an ester (probably acetate, phosphate, or sulfate group). Successively, the ester suddenly dissociates, the resultant electrophilic reactant is capable of alkylating the schistosome DNA (Imming et al., 2006; Pica-Mattocchia et al., 2006). The phytochemistry and therapeutic elucidation of *Datura stramonium* leaves extract has been well recognized in this investigation. In view of its multiple uses, more bioactive screening and structural elucidation studies are yet to be explored. The information presented in this work would be helpful in promoting research aiming at the development of methods for isolation and application of new agents for medical application and agro industries based on natural products derived from plants.

Conclusion

The information about jimson weed (leaves) covers many aspects including botanical, chemical, pharmaceutical and medical. The objectives of this study were to (a) develop an improved GC-MS procedure for the analysis of bioactive drug components in jimson weed leaves to show the known and unknown alkaloids, Flavonoids, Terpenoids, saponins, amide, amines and alcohols using GC-MS technique. These bioactives were identified, classified, characterized and estimated. They were blasted against the synthetic drug bank to ascertain their therapeutic relevance, correlation and relativity. Much of their pharmacological relevance was describe together with their mechanism of actions. This is with the believe that drugs producers, researchers and herbal technicians will find better understanding in redirecting their treatment.

References

1. Ahad HA, Babu UA, Nagesh K, Kiran DS, Madhavi KB (2012) Fabrication of glimepiride *Datura stramonium* leaves mucilage and

- poly vinyl pyrrolidone sustained release matrix tablets: in vitro evaluation. Kathmandu university journal of science, engineering and technology 8(1): 63-72.
2. Akharaiyi FC (2011) Antibacterial, Phytochemical and Antioxidant activities of *Datura metel*. International Journal of Pharm Tech Research 3(1): 478-483.
 3. American Psychiatric Association (1998) Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 155(5): 1-34.
 4. Angelakou A, Valsami G, Koupparis M, Macheras P (1993) Use of 1-anilino-8 naphthalenesulphonate as an ion probe for the potentiometric study of the binding of sulphonamides to bovine serum albumin and plasma. J Pharm Pharmacol 45(5): 434-438.
 5. Babiker F, Jamal P, Mirghani MES, Ansari AH (2017) Characterization, purification and identification of some Alkaloids in *Datura stramonium*. International Food Research Journal 24(Suppl): S540-S543.
 6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28(1): 235-42.
 7. Bhaskar CD, Seetaram M, Philip DC, Sabita N, Sakkarapalayam M, Todd E (2010) Synthesis of Function-Oriented 2-Phenyl-2H-chromene Derivatives Using L-Pipecolinic Acid and Substituted Guanidine Organocatalysts. Tetrahedron Letters 51(19): 2567-2570.
 8. Bratlid D, Bergan T (1976) Displacement of albumin-bound antimicrobial agents by bilirubin. Pharmacology 14(5):464-72.
 9. Buffett-Jerrott SE, Stewart SH. 2002. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des.8: 45-58.
 10. Chen X, Ji ZL, Chen YZ (2002) Therapeutic Target Database. Nucleic Acids Res 30(1): 412-5.
 11. Debasis S, Sunil KR, Hemlata G, Hasi RD (2015) A novel coumarin derivative, 8-methoxy chromen-2-one alleviates collagen induced arthritis by down regulating nitric oxide, NFkB and proinflammatory cytokines. International Immunopharmacology. <http://dx.doi.org/10.1016/j.intimp>.
 12. Derewlany LO, Knie B, Koren G (1994) Arylamine N-acetyltransferase activity of the human placenta. J Pharmacol Exp Ther 269(2): 756-60.
 13. Fan D, John J, Kriton KH (2005) Effects of lyphosate, chlorsulfuron, and methyl jasmonate on growth and alkaloid biosynthesis of Jimson weed (*Datura stramonium* L.). Pestic Biochem Physiol 84 (2): 155.
 14. Fick DM, Cooper JW, Wade WE (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 163: 2716-2724.
 15. Filho RP, de-Souza MCM, Pinto PL, Paula GA, Brandt CA, da-Silveira MA (2007) Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs. Bioorg Med Chem 15(3): 1229-36.
 16. Friaza V, Morilla R, Respaldiza N, de-laHorra C, Calderon EJ (2010) Pneumocystis jiroveci dihydropteroate synthase gene mutations among colonized individuals and Pneumocystis pneumonia patients from Spain. Postgrad Med 122(6): 24-8.
 17. Gachande BD, Khillare EM (2013) In-vitro evaluation of *Datura* species for potential antimicrobial activity. Bioscience Discovery 4(1): 78-81.
 18. Gaire BP, Subedi L (2013) A review on the pharmacological and toxicological aspects of *Datura stramonium* L. Journal of Integrative Medicine 11(2): 73-9.
 19. Guarrera PM (1999) Traditional antihelmintic, antiparasitic and repellent uses of plants in Central Italy. Journal of Ethnopharmacology 68(1-3): 183-192.
 20. Imming P, Sinning C, Meyer A (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5(10): 821-34.
 21. Ivancheva S, Nikolova M, Tsvetkova R (2006) Pharmacological activities and biologically active compounds of Bulgarian medicinal plants. Phytochemistry Adva Rese 87-103.
 22. Jalal HM (2016) Biological activities importance of Tetrazole derivatives. European Academic Research 3(12): 12796 – 2804.
 23. Jamal P, Akbar I, Hashim YZH, Jaswir I (2016) Process development for maximum lycopene production from selected fruit waste and its antioxidant and antiradical activity. Journal of Food Processing and Technology 7(4): 1-7.
 24. Katherine ZF (2016) Effects of Halobenzoquinone Water Disinfection By-Products on Human Neural Stem Cells. A thesis submitted for the degree of Master of Science. Department of Laboratory Medicine and Pathology, University of Alberta Pp.4.
 25. Lee M (2007) Solanaceae IV: *Atropa belladonna*, deadly nightshade. The Journal of the Royal College of Physicians of Edinburgh 37: 77-84.